BPC-157 and TB-500 together
Reviewed 18 sourcesPublished by PepVault
BPC-157 and TB-500 together: what the one controlled study of the pair found, the seven patients given both, how each peptide works and what users report.

- Last reviewed
- Sources
- 18
- Questions
- 7
- Compounds
- 3
The short answer
One controlled study has tested BPC-157 and TB-500 together. In 32 rats with repaired Achilles tendons, the pair did no better than either peptide alone, and only TB-500 alone made the tendons significantly stronger. In people, the record is seven patients in two uncontrolled reports, given BPC-157 with TB-500 or its parent protein. People stack them because each is known for a different side of repair.
Evidence: Animal and lab research for each peptide; for the pair, one controlled rat study and seven patients in two uncontrolled reports (a knee chart review and a jaw-nerve case report). No controlled human trial has tested TB-500 or the combination.
Has anyone tested BPC-157 and TB-500 together?
Yes, once, and the result cuts against the case for stacking. In a study published in July 2026, a team in Istanbul cut and stitched the Achilles tendons of 32 rats, then split them at random into four groups of eight: no treatment, BPC-157, TB-500, or both. Each rat got a daily injection into the belly cavity for four weeks, and then each tendon was either pulled until it failed or examined under the microscope1.
| Group | Tendon strength (load before failure) | Tissue scores |
|---|---|---|
| BPC-157 alone | Higher than untreated, but not significantly | Better on average, but not significantly |
| TB-500 alone | Significantly higher than untreated | Significantly better on both scoring systems |
| BPC-157 + TB-500 | No added benefit over either peptide alone | Significantly better on one of the two systems |
The authors' own summary is plain: the combination "did not confer additional benefits compared to either agent alone"1. Their explanation is that the two peptides may end up working through the same pathways downstream, so the second one has little left to add. They call that a hypothesis still to be tested, and they call the study exploratory1.
Read it for what it is. Eight rats per group is small, four weeks covers only the early phase of tendon repair, each peptide was tested at one dose, and the injections went into the belly cavity rather than near the tendon. The authors ask for dose-finding and longer studies next1. It is still the only controlled test of the pair in PubMed (October 2026), and it points one way: in this model, both peptides were linked to better-organized repair, TB-500 most clearly, and stacking them did not help more.

Has anyone taken both in a human study?
Seven people, in two small reports, and neither had a comparison group. A 2021 chart review from a clinic in Orlando, Florida, followed up 16 patients who had a peptide injected into a painful knee. Twelve got BPC-157 alone, and 11 of them reported significant improvement. The other four got two injections, BPC-157 and thymosin beta-4: three reported significant improvement and one had no relief2.
The study had no comparison group, patients rated their own pain by phone, most of them six months to a year after the injection, and no standard tools measured function or stiffness2. A narrative review led from NYU Langone, published in October 2026, describes BPC-157's entire human musculoskeletal evidence as one small, uncontrolled retrospective case series without validated outcome measures3, a description that fits this knee study.
The knee study names its second peptide only as thymosin beta-4 (TB4), so it does not say whether patients got the whole protein or the TB-500 fragment.
The other three come from a September 2026 case report led from Stony Brook University's dental school. Each patient had numbness after an injury to the nerve that runs through the lower jaw, and each got weekly injections near it for four weeks of a mix that held BPC-157 and TB-500 together with a third peptide, ARA-290, a steroid and a local anesthetic. All three regained near-complete feeling, and no side effects were reported. The authors say themselves that without a control group, natural recovery cannot be ruled out and the cases cannot show what caused it18. For the rest of BPC-157's human record, see our guide to the human data on BPC-157.
Is TB-500 the same as thymosin beta-4?
No, and the difference matters for how the evidence is read. Thymosin beta-4 is a natural protein of 43 amino acids4. Its main job inside cells is to hold single actin units, the building blocks of the cell's internal scaffolding, and keep them from joining into filaments. It sits at high levels in many cell types, and in resting human platelets it holds the bulk of the unassembled actin5.
TB-500 is a much smaller copy of one part of it. Anti-doping labs that analysed TB-500 products found the key ingredient is LKKTETQ, the seven-amino-acid stretch at positions 17 to 23 of thymosin beta-4, with an acetyl group added to one end67. In the words of one of those labs, that stretch is the part of the protein responsible for actin binding, cell migration and wound healing7. In aged mice, the seven-amino-acid piece on its own sped skin-wound repair about as well as the whole protein8.
The acetylated version sold as TB-500 has one twist. In a 2024 lab study, TB-500 itself showed no significant wound-closing activity on fibroblasts, the cells that build connective tissue, in a dish, while one of its breakdown products, Ac-LKKTE, did. The authors suggest that some of TB-500's reported effect may come from that fragment9. In rats, TB-500 broke down quickly into shorter pieces, one of which was still detectable in urine 72 hours later9.
The human trials belong to the whole protein. A placebo-controlled phase 2 trial in 73 patients with venous leg ulcers applied thymosin beta-4 to the skin, with safety comparable to placebo4. In a placebo-controlled study of 40 healthy volunteers, it was given by IV daily for 14 days and was well tolerated, with no serious adverse events10. The NYU review notes that TB-500 is often treated as the same thing as thymosin beta-4, with no proof that the two are biologically or clinically equivalent3. The FDA says it has not identified any human exposure data for TB-50011.
Why do people stack BPC-157 with TB-500?
Because on paper each one covers a different part of repair. BPC-157 is a chain of 15 amino acids, a piece of a larger protein first isolated from human gastric juice12. Picture it as a string of 15 beads, one per amino acid; the Peptide Sky below draws it that way, and TB-500 would be a string of just seven.
Peptide SkySee BPC-157 as a molecule53 peptides as a night sky in 3D. Each star opens into its molecule, one bead per amino acid, with the measured shape where one exists.Open the Peptide SkyIts strongest case is blood supply. In rats with a blocked leg artery, BPC-157 restored blood flow faster and grew more vessels, and in human blood-vessel cells in a dish it raised VEGFR2, the receptor that drives vessel growth13. It also acts on the repair cells of tendon: rat tendon cells treated with it grew out of tendon pieces faster, survived stress better and moved further12.
Thymosin beta-4's case is cell movement. Platelets release it at the site of an injury, where it starts the repair cascade14. In rats with full-thickness skin wounds, it increased new skin cover over the wound by 42% over saline at day 4 and by up to 61% at day 7, with more collagen and more new blood vessels15. In a dish, it made skin cells migrate two to three times more within hours15.
Put side by side, the split is less clean than the stack's reputation. In their own studies, BPC-157 and thymosin beta-4 both set repair cells moving, and both grew new blood vessels121315. That overlap fits the rat result: if two peptides push on the same machinery, the second one may add little1.
What do people who stack them report?
Commonly reported: faster recovery from tendon and ligament injuries, with stiffness easing in the first two weeks and the injury handling more load over weeks two to four. Mild irritation where the needle went in, and with TB-500 sometimes a day of tiredness or a short head rush, both of which pass on their own.
These are user reports, not trial results. They match the direction of the animal work for each peptide on its own. We found no study comparing people on the pair with people on one peptide alone.
Are BPC-157 and TB-500 approved or allowed in sport?
Neither has an FDA-approved use for muscle, tendon or bone, or a validated treatment protocol3. The FDA lists both among bulk substances nominated for pharmacy compounding and later withdrawn by the nominators. For each, it notes a possible risk of immune reactions by some routes and possible issues with peptide-related impurities, and for TB-500 it adds that it has found no human exposure data11.
For tested athletes, both are off limits at all times. The World Anti-Doping Agency's 2026 Prohibited List names BPC-157 under non-approved substances and "Thymosin-β4 and its derivatives e.g. TB-500" under growth factors16.
How can you tell whether the stack is working for you?
Start with a baseline. Before the first dose, write down how the injury moves, what hurts and how much load it takes, then check the same things weekly. Healing is gradual, and a record beats memory.
Change one thing at a time where you can. Starting two peptides on the same day, along with rest and rehab, makes it impossible to say which one did what, and the rat study suggests the second may not add much. A 2026 review in Sports Medicine also points to the placebo effect as part of how peptides seem to work, an effect it says social media makes stronger17. A written log is the best guard against both.
What would settle the question for people is a randomized trial with a group on each peptide alone and a group on the pair. We found none registered on ClinicalTrials.gov (October 2026). Until one reports, the honest summary is short: two peptides with real animal records of their own, and one small rat study suggesting that together they do not add up to more.
Sources
- Biçer O et al. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: a histopathological and biomechanical study. Jt Dis Relat Surg. 2026. PubMed 42542926
- Lee E, Padgett B. Intra-articular injection of BPC 157 for multiple types of knee pain. Altern Ther Health Med. 2021. PubMed 34324435
- Tham A, Hodgkins CW, Kennedy JG. Investigational peptides in orthopaedic practice: evidence, safety, and patient counseling for BPC-157, thymosin beta-4, and TB-500. J Am Acad Orthop Surg. 2026. PubMed 42937313
- Guarnera G et al. The effect of thymosin treatment of venous ulcers. Ann N Y Acad Sci. 2010. PubMed 20536470
- Safer D, Elzinga M, Nachmias VT. Thymosin beta 4 and Fx, an actin-sequestering peptide, are indistinguishable. J Biol Chem. 1991. PubMed 1999398
- Esposito S et al. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Test Anal. 2012. PubMed 22962027
- Ho EN et al. Doping control analysis of TB-500, a synthetic version of an active region of thymosin β4, in equine urine and plasma by liquid chromatography-mass spectrometry. J Chromatogr A. 2012. PubMed 23084823
- Philp D et al. Thymosin beta 4 and a synthetic peptide containing its actin-binding domain promote dermal wound repair in db/db diabetic mice and in aged mice. Wound Repair Regen. 2003. PubMed 12581423
- Rahaman KA et al. Simultaneous quantification of TB-500 and its metabolites in in-vitro experiments and rats by UHPLC-Q-Exactive orbitrap MS/MS and their screening by wound healing activities in-vitro. J Chromatogr B. 2024. PubMed 38382158
- Ruff D et al. A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers. Ann N Y Acad Sci. 2010. PubMed 20536472
- U.S. Food and Drug Administration. Certain bulk drug substances for use in compounding that may present significant safety risks (content current as of April 22, 2026). fda.gov
- Chang CH et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol. 2011. PubMed 21030672
- Hsieh MJ et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017. PubMed 27847966
- Treadwell T et al. The regenerative peptide thymosin β4 accelerates the rate of dermal healing in preclinical animal models and in patients. Ann N Y Acad Sci. 2012. PubMed 23050815
- Malinda KM et al. Thymosin beta4 accelerates wound healing. J Invest Dermatol. 1999. PubMed 10469335
- World Anti-Doping Agency. The 2026 Prohibited List: S0 non-approved substances and S2.3 growth factors. wada-ama.org
- Mendias CL, Awan TM. Safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance. Sports Med. 2026. PubMed 41966639
- Froum S et al. Case report: regenerative peptides for inferior alveolar nerve injury: a narrative review with hypothesis-generating three clinical cases. Front Oral Health. 2026. PubMed 42876687
Newsletter · Weekly
The weekly peptide briefing.
New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.